Cardiovascular adverse reactions during antidepressant treatment: A drug surveillance report of German-speaking countries between 1993 and 2010

International Journal of Neuropsychopharmacology

Volumn 18, Issue 4, 2014, Pages 1-9

  Spindelegger, Christoph Josef ^a   Papageorgiou, Konstantinos ^a   Grohmann, Renate ^e   Engel, Rolf ^e   Greil, Waldemar ^c,e   Konstantinidis, Anastasios ^a   Agelink, Marcus Willy ^b   Bleich, Stefan ^d   Ruether, Eckart ^e   Toto, Sermin ^d   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Psychiatric Private Hospital   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidepressant; Cardiovascular side effects; QT prolongation; SSRI; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COLLAPSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; RISK FACTOR; AUSTRIA; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; GERMANY; MIDDLE AGED; SWITZERLAND;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIDEPRESSIVE AGENTS; AUSTRIA; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SWITZERLAND;

EID: 84939151318     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu080     Document Type: Article

References (47)

1. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S (2008) Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 17:587-592.
2. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH (2013) QT interval and antidepressant use: a cross sectional study of electronic health records. The BMJ 346:f288.
3. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley- Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. The BMJ 343:d4551.
4. Davison ET (1985) Amitriptyline-induced Torsade de Pointes. Successful therapy with atrial pacing. J Electrocardiol 18:299-301.
5. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K (2012) Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J 39:68-70.
6. EMA PWPP (2011) Pharmacovigilance Working Party (PhVWP). EMA/CHMP/PhVWP/845939/2011. http://www.ema.europa.eu/ docs/en-GB/document-library/Report/2011/10/WC500117061.pdf.
7. FDA (2011) FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). http://www.fda.gov/Drugs/DrugSafety/ ucm269086.htm.
8. Feighner JP (1995) Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56:574-579.
9. Fernandez A, Bang SE, Srivathsan K, Vieweg WV (2007) Cardiovascular side effects of newer antidepressants. Anadolu Kardiyol Derg 7:305-309.
10. Friberg LE, Isbister GK, Duffull SB (2006) Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 61:177-190.
11. Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P (2013) Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psych 170:1468-1476.
12. Glassman AH, Bigger JT, Jr. (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 38:815-820.
13. Glassman AH, Bigger JT, Jr., Giardina EV, Kantor SJ, Perel JM, Davies M (1979) Clinical characteristics of imipramineinduced orthostatic hypotension. Lancet 1:468-472.
14. Glassman AH, Roose SP, Bigger JT, Jr. (1993) The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 269:2673-2675.
15. Grimsley SR, Jann MW (1992) Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11:930-957.
16. Grohmann R, Ruther E, Engel RR, Hippius H (1999) Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 32:21-28.
17. Grohmann R, Engel RR, Ruther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4-11.
18. Hurwitz N, Wade OL (1969) Intensive hospital monitoring of adverse reactions to drugs. The BMJ 1:531-536.
19. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1):19-26.
20. Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11(Suppl 4):35-39.
21. Kasper S, Moller HJ, Hale A (2010) The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 260:59-68.
22. Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S (2012) Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychop 15:449-457.
23. Kozian R, Syrbe G (2010) QTc prolongation during treatment with agomelatine. Psychiatr Prax 37:405-407.
24. Lentini S, Rao ML, Schroder R, Luderitz B, Bauriedel G (2001) QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects. Dtsch Med Wochenschr 126:1396-1400.
25. Leonard BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54(Suppl 8):3-15.
26. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S (2011) Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 20:903-913.
27. Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2011) Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychop 15:739-748.
28. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F (2006) QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109:116-117.
29. Mackin P (2008) Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23(Suppl 1):3-14.
30. Martinez C, Assimes TL, Mines D, Dell'aniello S, Suissa S (2010) Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested casecontrol study. The BMJ 340:c249.
31. Pacher P, Kecskemeti V (2004) Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 10:2463-2475.
32. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V (1999) Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 6:469-480.
33. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT (2004) Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 75:234-241.
34. Sadanaga T, Sadanaga F, Yao H, Fujishima M (2004) Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol 37:267-273.
35. Schmid C, Grohmann R, Engel RR, Ruther E, Kropp S (2004) Cardiac adverse effects associated with psychotropic drugs. Pharmacopsychiatry 37(Suppl 1):S65-69.
36. Seidl LG, Thornton GF, Cluff LE (1965) Epidemiological Studies of Adverse Drug Reactions. Am J Public Health Nations Health 55:1170-1175.
37. Stahl SM, Grady MM, Moret C, Briley M (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732-747.
38. Thase ME (1998) Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508.
39. Thase ME, Larsen KG, Reines E, Kennedy SH (2013) The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 23:1391-1400.
40. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH (2009) Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 29:9-15.
41. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26:997-1012.
42. Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809-824.
43. Volz HP, Gleiter CH (1998) Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 13:341-355.
44. Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC (2006) QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psych 163(2):325.
45. Winkler D, Ortner R, Pjrek E, Aschauer H, Kasper S (2006) Trazodone- induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol 21:61-62.
46. Zemrak WR, Kenna GA (2008) Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 65:1029-1038.
47. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M (2007) QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 49:146-153.